Orexo Interim Report Q3 2024 [Yahoo! Finance]
OREXO AB SP/ADR (ORXOY)
NASDAQ:AMEX Investor Relations:
orexo.com/en/investors
Company Research
Source: Yahoo! Finance
› Total net revenues of SEK 136.5 m › EBITDA of SEK -0.7 m › Net earnings of SEK -41.9 m › US Commercial segment net revenues of SEK 131.0 m (140.4), in local currency USD 12.6 m (13.0) › Cash flow from operating activities of SEK -13.4 m (-21.9), cash and cash equivalents of SEK 114.9 m (184.2) › Earnings per share before and after dilution amounted to SEK -1.21 › Orexo AB's sustainability work ranked among the top five percent of all 70,000 businesses worldwide reviewed by EcoVadis › For OX124, our high dose naloxone rescue medication for opioid overdose, a complete response letter was received from the FDA requesting additional technical data on the final commercial product as well as further information from a new human factors study (HF study). A new HF study was successfully conducted in July. › The financial guidance for 2024 reiterated. Important events after the end of the period › An exploratory phase 1 clinical study was initiated for OX640 in participa
Show less
Read more
Impact Snapshot
Event Time:
ORXOY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORXOY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORXOY alerts
High impacting OREXO AB SP/ADR news events
Weekly update
A roundup of the hottest topics
ORXOY
News
- Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology [Yahoo! Finance]Yahoo! Finance
- Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technologyPR Newswire
- Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technologyPR Newswire
- Orexo initiates new study of OX640 in participants with allergic rhinitis [Yahoo! Finance]Yahoo! Finance
- Orexo initiates new study of OX640 in participants with allergic rhinitisPR Newswire